{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-25-000033","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2025-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.087574+00:00","generated_at":"2026-05-24T14:21:37.328563+00:00","sec_items":["2.02","4.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Maravai restates Q2/Q3 2024 financials due to $3.9M revenue recognition error; Q4 revenue down 24%","bullets":["Non-reliance on Q2 and Q3 2024 financials; restatement corrects $3.9M revenue timing error.","Q4 revenue $56.6M (-23.7% YoY); Adjusted EBITDA loss of $1.1M vs +$20.5M a year ago.","Full year 2024 revenue $259.2M (-10.3% YoY); net loss $259.6M includes $166M goodwill impairment.","Voluntarily prepaid $228M of Term Loan with cash; year-end cash $322M.","Appointed healthcare industry veteran R. Andrew Eckert as independent Chairman."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-25-000033","json":"https://secwatch.observer/filing/0001823239-25-000033.json","markdown":"https://secwatch.observer/filing/0001823239-25-000033.md","text":"https://secwatch.observer/filing/0001823239-25-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323925000033/0001823239-25-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323925000033/mrvi-20250317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T14:21:37.328563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}